T he growth of new blood vessels plays an important role in many disease processes, including chronic ischemic cardiovascular disease, wound healing, and cancer. For tumors, angiogenesis appears to be a critical determinant of growth, invasion, and metastatic potential. [1] [2] [3] Noninvasive imaging techniques to assess tumor angiogenesis are currently being developed to diagnose primary and metastatic disease and to assess prognosis. Most new methods for evaluating angiogenesis rely on the detection of abnormal perfusion, microvascular blood volume, or vascular permeability. An alternate strategy is to detect abnormal vascular endothelial cell phenotype. Detection of ␣ v -integrin expression in tumor neovessels may be particularly advantageous, since these integrins appear to play a functional role in angiogenesis 4, 5 and have been implicated as a marker of metastatic potential and poor prognosis in certain tumors. 6 Assessing tumor vascular phenotype may also provide im-portant information on susceptibility to novel antiangiogenic tumoricidal therapies.
Contrast-enhanced ultrasound (CEU) with targeted microbubble contrast agents has recently been used to noninvasively assess expression of endothelial cell adhesion molecules in vivo. 7, 8 Microbubbles targeted to ␣ v -integrins by conjugation of the disintegrin echistatin to their shell surface have recently been developed that adhere to the endothelial surface of FGF-2-treated microvessels and to matrigel neovessels. 9 In this study, we hypothesized that microbubbles targeted to ␣ v ␤ 3 could be used to noninvasively evaluate tumor angiogenesis with ultrasound. To test our hypothesis, targeted imaging of a malignant glioma model in rats was performed and compared with data on tumor blood flow and neovascular blood volume derived from established techniques for CEU perfusion imaging.
Methods

Microbubble Preparation
For targeted microbubbles, biotinylated microbubbles were first prepared by sonication of an aqueous dispersion of decafluorobutane gas, distearoylphosphatidylcholine (Avanti Polar Lipids), polyethyleneglycol-(PEG-) stearate (Sigma), and distearoylphosphatidylethanolamine-PEG-biotin (prepared from components from Avanti Polar Lipids, Shearwater Polymers). Microbubbles were combined with streptavidin (Sigma), washed, and combined with biotinylated echistatin (Sigma). 9 Control lipid microbubbles without echistatin were also prepared. For confocal microscopy, microbubbles were fluorescently labeled by dioctadecyl tetramethylindocarbocyanine (DiI) (Molecular Probes). 9 For perfusion imaging, nontargeted, lipid-shelled microbubbles (MP1950) were prepared. 10 Microbubble size distribution was determined by electrozone sensing (Coulter Multisizer IIe, Beckman-Coulter).
Glioblastoma Tumor Model
Tumors were created by intracerebral implantation of human glioma cells in athymic rats (Hilltop Lab Animals, Inc, Scottdale, Pa). Eighteen rats were anesthetized with ketamine (40 mg/kg) and xylazine (8 mg/kg). Under sterile conditions, a small skin incision was made and a 2-mm burr hole was made in the parietal bone of the skull. In 14 of these rats, 1ϫ10 5 U87MG cultured human glioma cells embedded in absorbable gelatin matrix were stereotactically implanted through the burr hole into the cerebral hemisphere at a depth of 4 to 6 mm. Gelatin matrix alone was implanted into 4 control rats. The incision was closed and animals were studied at either 14 (nϭ5) or 28 (nϭ9) days after U87MG cell implantation and at 28 days for control rats.
Contrast-Enhanced Ultrasound Imaging
For contrast administration, a jugular vein was cannulated with PE50 tubing. CEU of the brain was performed in the mid-coronal plane using gray-scale pulse-inversion imaging (HDI 5000, Philips Ultrasound) and a linear-array transducer (L7-4). Transmission frequency of 3.3 MHz and a mechanical index of 0.8 were used. The acoustic focus was placed at the mid-brain level. Gain settings were optimized and kept constant throughout the experiments.
Targeted Imaging
Data were acquired 10 minutes after bolus intravenous injection of 1ϫ10 8 ␣ v ␤ 3 -targeted or control microbubbles, performed in random order. The initial frame, containing signal from both retained and any freely circulating microbubbles, 10 was captured. Microbubbles were then destroyed with continuous (Ն30 Hz) high-power imaging for 3 seconds. Several frames subsequently obtained at a pulsing interval (PI) of 20 seconds, containing contrast-enhanced signal only from freely circulating microbubbles, were averaged and digitally subtracted from the initial frame to derive the signal from retained microbubbles alone. 10 Since the number of microbubbles retained depends on both binding kinetics and regional microbubble influx, the image representing retained microbubbles was normalized to parametric blood flow data (below) to derive a parametric colorcoded image uniquely reflecting the microbubble retention fraction.
Perfusion Imaging
Microvascular perfusion was measured by means of intermittent imaging at a mechanical index of 0.9 to 1.0 during a continuous intravenous infusion of MP1950 (10 to 12.5 L/min), as previously described. 11, 12 Acoustic intensity (AI) was measured within regions of interest determined from review of corresponding histologic sections. PI versus AI data were fit to the function yϭA (1Ϫe Ϫ␤t ), where y is AI at the pulsing interval t, A is plateau intensity or microvascular blood volume, and ␤ is the rate constant reflecting microvascular red blood cell (RBC) velocity. 12 Blood flow was determined by the product of A and ␤. Parametric images of A, ␤, and Aϫ␤ were derived by fitting the 1-exponential function to data on a pixel-by-pixel basis.
Histology and Immunohistochemistry
Immunostaining was performed on paraffin-embedded sections. For detecting ␣ v -integrin expression, an affinity-purified rabbit polyclonal antibody against rat ␣ v subunit (AB1930, Chemicon International) was used as a primary antibody. A biotinylated goat anti-rat antibody (Vector laboratories) was used as a secondary antibody. Staining was performed using a peroxidase kit (ABC Vectastain Elite, Vector Laboratories) and 3,3Ј-diaminobenzidine chromogen (DAKO). Slides were counterstained with hematoxylin. For control purposes, staining was also performed with secondary antibody alone, which did not demonstrate any nonspecific staining. Hematoxylin and eosin staining was also performed on paraffin-embedded sections, and mean tumor size was determined by the largest area in the coronal plane. These sections were used to register imaging data for performing regional analysis of perfusion and targeted microbubble signal.
Confocal Microscopy
Fluorescent confocal microscopy was performed in 4 rats 28 days after U87MG implantation. A single intravenous injection of either 1ϫ10 8 di-I-labeled control or ␣ v ␤ 3 -targeted microbubbles was performed in 2 animals for each agent. After 10 minutes, 1 mg fluorescein Lycopersicon esculentum lectin (Vector laboratories) in saline was infused. Perfusion fixation was performed with 4% paraformaldehyde in PBS, and thick sections of the brain were examined with a confocal laser scanning microscope (LSM510, Carl Zeiss Inc) (ϫ20 objective) and dual fluorescence overlays. Observations were made in 15 to 20 optical fields throughout the tumor and contralateral normal hemisphere.
Statistical Methods
Data are expressed as meanϮ1 SD. Comparisons of continuous variables were made by means of the unpaired Student's t test. Bonferroni's correction was applied for multiple comparisons. Correlations between targeted contrast ultrasound signal and blood volume were made by linear regression analysis. Differences were considered significant at PϽ0.05 (2-sided).
Results
Tumor Histology
All control rats and 12 of 14 injected with U87MG cells survived to their assigned follow-up period. Tumors were detected by histology in all animals undergoing U87MG implantation ( Figure 1A ). Mean tumor size measured in the coronal plane was substantially greater at 28 versus 14 days 
Ellegala et al Tumor Angiogenesis and Contrast Ultrasound
(35Ϯ14 versus 2Ϯ1 mm 2 , PϽ0.001). Immunohistology demonstrated ␣ v -integrin expression on the microvascular endothelium of tumor neovessels ( Figure 1B) , the density of which was greatest at the outer margins of the tumor. Microvascular endothelial ␣ v -integrin staining was also observed heterogeneously in nonneoplastic tissue immediately adjacent to the tumors ( Figure 1B ) but not in control regions contralateral to the tumors or in regions injected with gelatin matrix vehicle in the control rats.
Tumor Perfusion by CEU
Illustrated in Figure 2 are CEU images and corresponding pulsing interval versus acoustic intensity data demonstrating microvascular perfusion abnormalities in a rat 28 days after U87MG implantation. In this example, the glioma was characterized by slower blood velocity but slightly greater microvascular blood volume compared with normal parenchyma from the contralateral hemisphere. A gradient of microvascular blood velocity from peripheral to central portions of the tumor can be discerned. The results for all rats are depicted in Figure 3 , where data from tumors or from regions of gelatin vehicle implantation are normalized to the contralateral normal hemisphere. In control animals, no abnormalities in microvascular blood volume, blood velocity, or blood flow were seen in regions of gelatin vehicle implantation. In tumors, normalized microvascular blood volume was significantly lower than control regions at 14 days but increased by day 28. Microvascular blood velocity progressively decreased with tumor growth. At day 28, mean blood velocity (␤) was lower in the central compared with outer half of the tumor (0.14Ϯ0.02 versus 0.28Ϯ0.10 s Ϫ1 , PϽ0.05).
Normalized blood flow also tended to decrease with tumor growth, and was lower in the inner compared with outer half of the tumor (0.45Ϯ0.19 versus 0.70Ϯ0.10, PϽ0.05) at day 28. In nonneoplastic parenchyma immediately surrounding the tumor, increased microvascular blood flow was often observed with abundant high-velocity vessels ( Figure 2B ). However, blood flow in these regions was sometimes reduced when tumor size was large, possibly from tumor compression ( Figure 4B ).
Targeted CEU Imaging of ␣ v -Integrin Expression
The mean diameter of control and ␣ v ␤ 3 -targeted microbubbles was not significantly different (3.3Ϯ0.4 versus 3.1Ϯ0.4 m). On confocal microscopy, microbubble retention was observed within tumor microvessels at 28 days for ␣ v ␤ 3 -targeted (range, 7 to 20 per 10 optical fields) but not control microbubbles (Յ1 per 10 optical fields) ( Figure 4A ). Retention of targeted microbubbles was most frequently detected in small (Ͻ15 m diameter) neovessels, although retention was occasionally seen in larger vessels at the tumor margins. Microbubbles were not observed in the extravascular space and were rarely observed in contralateral control regions (Յ1 per 20 optical fields). Contrast ultrasound performed 10 minutes after injection of ␣ v ␤ 3 -targeted microbubbles demonstrated intense signal enhancement within the tumors and lower intensity enhancement in surrounding nonneoplastic brain parenchyma ( Figure  4B ). Signal enhancement with targeted microbubbles was also seen in the few cases of metastatic seeding of the meninges ( Figure 4B ). Results from all animals are depicted in Figure 5 . For control microbubbles, signal enhancement in tumors or in regions of gelatin matrix implantation relative to the contralateral normal hemisphere was low. Signal enhancement was also low for ␣ v ␤ 3 -targeted microbubbles in control regions implanted with gelatin matrix. The relative signal from ␣ v ␤ 3 -targeted microbubbles in tumors was much greater than in control regions and was higher for tumors at 28 compared with 14 days. The relative signal was higher for the outer versus the inner half of the tumor at 28 days, although this difference reached only borderline statistical significance (3.3Ϯ1.0 versus 2.4Ϯ0.4, Pϭ0.06). The CEU signal from ␣ v ␤ 3 -targeted microbubbles correlated well with microvascular blood volume within the tumors derived from contrast ultrasound perfusion imaging ( Figure 6 ).
Discussion
In this study, we have demonstrated for the first time that tumor angiogenesis can be assessed with ultrasound imaging and microbubbles targeted to ␣ v -integrins. These data com-bined with CEU-derived regional tissue blood velocity, volume, and flow are likely to provide important physiological insights into angiogenesis associated with neoplastic and chronic ischemic cardiovascular diseases.
The growth of most solid tumors is highly dependent on local vascular proliferation. The ability to image angiogenesis may, therefore, provide a sensitive means to diagnose malignancies and to predict their rapid expansion. Assessing angiogenic phenotype may also provide important information on metastatic potential since abnormalities of neovascular architecture and permeability are thought to facilitate tumor cell shedding into the circulation. 3 Vascular density has been shown to correlate with the likelihood of metastasis and the overall prognosis for patients with several types of cancers. 3, 13, 14 In this study, we examined malignant gliomas, which are highly dependent on angiogenesis for growth and invasion. 15 Angiogenesis was assessed by using two different CEU techniques. Molecular characterization was performed with a novel microbubble contrast agent targeted to ␣ v ␤ 3 . This integrin is highly expressed by angiogenic endothelium and is thought to play a functional role in matrix remodeling, and anchorage-dependent endothelial migration and proliferation. 4, 5, 16 Vascular expression of ␣ v ␤ 3 has also been shown to predict metastasis and poor survival. 6 Microbubbles were targeted by conjugation of echistatin to the shell surface. This peptide derived from the venom of the viper Echis carinatus bears the RGD motif and has enhanced binding affinity for ␣ v ␤ 3 over nonactivated ␣ 2b ␤ 3 . 17 Echistatin-bearing microbubbles have been shown to adhere to the endothelial surface of microvessels treated with sustained-release FGF-2 and produce strong ultrasound signal enhancement in subcutaneous matrigel models of angiogenesis in mice. 9 Although targeting ␣ v -integrins in tumors has been explored with magnetic resonance and positron emission tracers, 18, 19 we believe that microbubbles are ideal for detecting vascular endothelial phenotype alone since they are not diffusible and are confined to the vascular compartment.
The functional aspect of angiogenesis was also evaluated in this study by quantifying microvascular perfusion with nontargeted microbubbles. Perfusion patterns on CEU have been used previously to differentiate malignant from benign tumors in the liver 20 and to enhance sensitivity of ultrasound for diagnosing breast and prostate tumors. 21, 22 However, correlation between CEU data and tumor vascularity on histology has been met with mixed results. [23] [24] [25] One reason for discordance is that the extent of tumor angiogenesis may not necessarily be reflected by perfusion due to low functional efficiency of tumor neovessels. In other words, the percentage of vessels with flow at any given point of time may be low. 26 Another more practical reason has been the use of high frame rate, high power imaging techniques that preferentially detect flow in large rather than small vessels. We instead used imaging techniques and off-line processing that provides information on microvascular perfusion 11 and that has been shown to be accurate for assessing malignant neovascularization. 25 The results from molecular and perfusion imaging at different time intervals in this study are congruent with the 
Ellegala et al Tumor Angiogenesis and Contrast Ultrasound
angiogenic progression for malignant gliomas. Intravital microscopy of gliomas has revealed an initial avascular slow growth phase in the first week followed by vascular budding in adjacent tissues and early development of a disordered tumor microcirculation with low functional efficiency in the second week. 26, 27 Accordingly, we found that microvascular blood volume in tumors at 14 days after U87MG implantation was lower than in normal brain parenchyma. Yet, early neovessel development was detected by enhanced signal from ␣ v ␤ 3 -targeted microbubbles. By 28 days, when glioma neovascularization is advanced, 26, 27 microvascular blood volume by CEU had increased and was generally slightly greater than normal tissue. A strong signal from ␣ v ␤ 3 -targeted microbubbles was obtained at this time and was greatest at the outer margins of the tumor, where angiogenic activity is the greatest 26 and where ␣ v -integrin staining was most prominent on immunohistology. Despite an increase in microvascular blood volume from 14 to 28 days, mean blood flow for the entire tumor progressively decreased due to a reduction over time in RBC velocity in the glioma microcirculation. The radial gradient in RBC velocity in gliomas at 28 days has been similarly been observed with microscopy. 26 These spatial heterogeneities in perfusion have been attributed to altered fractal dimensions, increased interstitial pressures, and abnormal vasoregulatory and hemorheologic properties and are responsible in part for predictable spatial heterogeneities in pH and oxygen that influence tumor growth and necrosis. 28, 29 At both 14 and 28 days after U87MG implantation, ␣ v ␤ 3 -targeted microbubbles produced signal enhancement in nonneoplastic brain parenchyma surrounding the tumors. Expression of ␣ v -integrins on the endothelium of microvessels was found occasionally in these regions, consistent with vascular remodeling required for microvascular sprouting from adjacent normal tissue. 30 Although signal-enhancement from ␣ v ␤ 3 -targeted microbubbles in adjacent nonneoplastic parenchyma overestimates tumor size, it may also enhance sensitivity for detecting very small tumors or metastases.
Several limitations of the study should be noted. Although the signal from ␣ v ␤ 3 -targeted microbubbles correlated closely with the extent of angiogenesis, gliomas were evaluated early during rapid growth phase when vascular ␣ v -integrin expression is likely to be greatest. Whether ␣ v ␤ 3 -integrin imaging will be useful later in the angiogenic progression needs to be determined. The ligand echistatin can also bind other endothelial ligands such as ␣ 5 ␤ 1 , the expression of which is also increased in neovascular endothelium. However, any strategy that uses small peptides for targeting ␣ v ␤ 3 is likely to be limited by some degree of binding to other RGD-binding integrins. Although the number of animals was small, we believed the marked differences in targeted microbubble signal did not justify continued investigation. A new method for deriving retention fraction was developed since the number of retained microbubbles is dependent not only on binding kinetics but also on regional blood flow, which determines microbubble influx. This method assumes that binding efficiency is not influenced by blood flow or microvascular velocity. This assumption is, however, based on our in vivo and flow chamber observations that targeted micro-bubble retention is influenced mostly by ligand density and is relatively independent of shear stresses at or below physiological values. 7 The image processing algorithms used relied on digital subtraction of log-compressed rather than linear acoustic intensity data. Use of log-compressed data for perfusion assessment has been validated previously against radiolabeled microsphere measurements 12 and is relatively accurate since received signal intensities are still relatively low where log and linear data are similar. Finally, we did not directly correlate microbubble density on confocal microscopy to signal intensity because of the highly deformable nature of the thick sections which precluded estimation of tissue volume. The purpose of confocal microscopy was instead to make qualitative descriptions of the location of microbubble retention and to exclude aggregation or extravasation.
We conclude that microbubbles targeted to ␣ v -integrins can be used to image and spatially assess angiogenic responses that occur early in the development of malignant gliomas. Further investigation will be needed to determine whether targeted imaging of angiogenic phenotype in different tumor types provides additional diagnostic and prognostic information to imaging methods already used in the clinical setting.
